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]ME effect of FK506 and cyclosporin A (CsA) on the pro-
duction of interleukin 6 (IL-6) in adherent monocytes
was studied at a single-cell level by the avidin-
biotin-peroxidase complex methods. The percentage of
IL-6-producing monocytes increased when stimulated
with lipopolysaccharide (LPS) at concentrations between
10 ng/ml and 10 lig/ml, in a dose dependent manner.
Both FK506 and CsA enhanced the percentage of IL-6-
producing monocytes stimulated with 100 pg/mI-1 tg/
ml ofLPS up to values near those obtained with 10 tg/ml
ofLPS. The enhancement by FK506 and CsAwas not seen
when monocytes were stimulated with a high concentra-
tion ofLPS (10 tg/ml). When monocytes were stimulated
with a low concentration of LPS (10 ng/ml), FK506 and
CsA enhanced IL-6 production in a dose dependent man-
ner, at a drug concentration of 0.12 nM-l.2 tM
(0.1-1 000 ng/ml) for FK506 and 0.83 riM-8.3 tM
(1-10 000 ng/ml) for CsA. The optimal effect of FK506
was achieved at a concentration 7-fold lower than that of
CsA. In contrast, production of turnout necrosis factor-
(TNF00 and interleukin1 (IL-I)was slightly suppressed
byFK506 and CsA at the concentrations tested. Moreover,
pretreatment of monocytes with FK506 and CsA had a
significant enhancing effect on LPS-induced IL-6 produc-
tion, while treatment with FK506 or CsA after LPS stimu-
lation had no effects on IL-6 production, suggesting that
the enhancing effect of each drug is exerted before LPS
stimulation or at an early stage ofthe post-receptor path-
way after LPS stimulation. These experiments demon-
strate that FK506 and CsA can selectively enhance IL-6
production in monocytes under certain conditions in
vitro and, possibly, also in vtvo.
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Introduction
Cyclosporin A (CsA) is a representative
immunosuppressive drug, effective in the treatment
of haematologic disorders such as aplastic anaemia
and pure red cell aplasia. FK506, a macrolide antibi-
otic obtained from Streptomyces tsukubaensis," has a
powerful and selective anti-T cell effect, similar to
that of CsA. Moreover, some biological roles for the
two agents, distinct from T-cell immunosuppression,
have been defined.7-9 However, their effects on hu-
man monocytes are still unclear. Monocytes can
produce several cytokines such as interleukin 6 (IL-
6),
1 tumour necrosis factor-z (TNF00 and interleukin
1 (IL-I). Andersson et al. 11 reported these two
drugs had no effect on IL-6 production in monocytes
after LPS stimulation.
The present study examined whether FK506
and CsA would influence the production of IL-6 in
monocytes at a single-cell level by the
avidin-biotin-peroxidase complex (ABC) methods.
It is shown here that FK506 and CsA selectively
( 1994 Rapid Communications of Oxford Ltd
enhance the number of IL-6 producing monocytes
when stimulated with low concentrations of LPS,
although neither of them had an enhancing effect
when monocytes were stimulated with a high con-
centration of LPS.
Materials and Methods
Immunosuppressants: FK506 (molecular weight
(MW) 1202.63) was kindly provided by Fijisawa
Pharmaceutical Co. Ltd (Osaka, Japan). Cyclosporin
A (CsA) (MW 822.05) was purchased from Sandoz,
Ltd (Tokyo, Japan). FK506 was diluted in 100%
ethanol to a concentration of 1.2 mM (1 mg/ml) and
further diluted with RPMI 1640 culture medium to
obtain working concentrations. CsA was diluted with
RPMI 1640. Both drugs were used without preserva-
tives and were freshly prepared for each experiment.
Preparation of multiple-square slides: Multiple-
square slides with 3 x 7 squares (4 mmx 4 mm)
were made on glass slides by drawing straight paral-
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lel vertical and horizontal lines with a PAP Pen
(Daido Sangyo Co., Ltd, Japan). Hydrophobic lines
prevent aqueous solutions in separate wells from
leaking out.
Monocyte separation and cytokine induction:
Mononuclear cells (MNC) were isolated from freshly
drawn blood from healthy blood donors by centrifu-
gation on a density gradient (Lymphocyte separation
medium, Organon Teknika Corporation, Durham,
NC). Cells (2 x 106 cells/ml) were then suspended in
RPMI 1640 medium supplemented with endotoxin
free 5% foetal bovine serum (FCS), 2 mM t-glutamine,
100 U/ml penicillin and 100 t.tg/ml streptomycin. Ten
l.tl of the cell suspension was placed in each well of
multiple-square slides and allowed to adhere for
30 min at 37C in a humidified atmosphere contain-
ing 5% CO2. After incubation, the non-adherent cells
were removed by washing with PBS. The plating
efficiency of the monocytes was more than 90%. The
monocyte purity was more than 98% as assessed by
morphology, peroxidase and non-specific esterase
staining. This culture medium was endotoxin free as
determined by the Limulus amoebocyte lysate assay
(less than 0.2ng/ml of endotoxin). Monocyte
monolayers were overlaid with fresh culture medium
(1% FCS-RPMI 1640) and cultured in the presence of
10 ng/ml of lipopolysaccharide (LPS) from
Escherichia coli serotype 026:B6 (Sigma Chemical
Co, St Louis, MO) for 4 h. After culture, the cells were
immediately fixed for detection of cytokine-produc-
ing cells by ABC method. In some experiments, the
monocytes were cultured with various concentra-
tions of LPS.
Dose-response curves for FK506 and CsA: FK506
was used at 10-fold dilutions in each experiment
from culture concentrations of 12 pM-1.2 l.tM
(0.01-1 000 ng/ml). CsA was used at concentrations
of 83 pM to 8.3 t-tM (0.1 to 10 000 ng/ml). The two
drugs were added from the beginning of the cultures
with or without LPS and were present throughout the
culture period. LPS-activated monocytes, without
FK506 or CsA, served as positive controls. The cells
were fixed to detect cytokine-producing cells 4 h
after the initiation of LPS stimulation.
Pretreatment and post-treatment by FK506 or CsA:
Monocytes were incubated with or without 12 nM
(10 ng/ml) FK506 or 0.83 l.tM (1 000 ng/ml)
cyclosporin A for 1 h before LPS stimulation. After
washing the monocytes with PBS, 10 ng/ml LPS was
added to part of the cultures and these were incu-
bated for various periods of time. After washing the
monocytes with PBS, 10 l.tl of 1% FCS-RPMI 1640 was
added to the wells and culture was continued. In
some experiments, monocytes were stimulated with
10 ng/ml LPS for 30 min washed with PBS and then
incubated with or without 12 nM (10 ng/mD FK506
or 0.83 l-tM (1 000 ng/ml) CsA for 1 h or 3.5 for both.
After washing them with PBS, 10 I.tl of 1% FCS-RPMI
1640 was added to the wells and culture was contin-
ued. The cells on multiple-square slides were fixed
to detect cytokine-producing cells 4 h after the initia-
tion of LPS stimulation.
Immunocytochemical staining of cytokines: Enzyme
immunocytochemistry was performed essentially as
previously described to detect cytoplasmic cytokines
by an indirect immunofluorescence technique.
12
The cells fixed in phosphate buffered 4%
paraformaldehyde were stained using the ABC
method. They were then incubated for 30 min with
cytokine specific mAb diluted in 0.1% saponin at
room temperature. The following mAb were used at
a final concentration of 2 l.tg/ml: anti-IL-6 mAb
(mouse IgG1, Genzyme Co., Boston, MA); anti-TNF0t
mAb (Clone 195, mouse IgG3, Boehringer Mannheim
GmbH, Mannheim, Germany); and anti-IL-l[ (mouse
IgG1, Genzyme Co.). After washing the mAb three
times with phosphate buffered saline (PBS)
containing 1% Tween 20 and 0.1% saponin, they
were incubated with biotin conjugated horse anti-
mouse IgG sera diluted in 0.1% saponin-PBS for 20
min. Heat-inactivated human AB serum (5%) was
used in this step to reduce nonspecific protein inter-
action. In the subsequent procedures Vestastain alka-
line phosphatase ABC reagents (Vector Laboratories
Inc., Burlingame, CA) were used. The specimens
were developed in substrate containing 1 mmol/1
levamisole to block endogenous enzymes. The
specimens were not counterstained. Control cells for
each experiment were stained with a myeloma
protein of identical subclass (IgG1 and IgG3) at a
final concentration of 2 l.tg/ml. The results are given
as the percentage of positively stained cells. This was
done by counting more than 500 cells. Unstimulated
cells were used as negative controls in each experi-
ment. The S.D. within a multiple-square slide or
among different slides was less than 10% of the mean
value.
Statistical evaluation: The results are expressed as
the mean values +_ S.D. The statistical significance of
differences was determined by Student’s t-test.
Results
Effect ofFK506 or CsA on LPS-induced cytokinepro-
duction in monocytes: The effect of FK506 and
cyclosporin A on cytokine production was studied
using an immunocytochemical technique at a single-
cell level. Monocytes were cultured with 10 ng/ml
LPS for 4 h. With this technique, a local perinuclear
cytoplasmic staining pattern was seen in IL-6
producing monocytes (Fig. 1A) as well as TNF-
producing monocytes, while IL-l[-producing
376 Mediators of Inflammation Vol 3. 1994FK506 and CsA enhance IL-6production in monocytes
FIG. 1. Immunocytochemical staining of IL-6-producing monocytes 4 h
after initiation of culture with LPS (10 ng/ml). (A) IL-6-producing monocytes.
(B) IL-11-producing monocytes. Bar, 30 lm.
monocytes showed a diffuse cytoplasmic staining
pattern (Fig. 1B).
While cytokine production was rarely seen in the
absence of LPS (< 2% monocytes), in vitro stimula-
tion with LPS resulted in a prompt increase of IL-6,
TNFc and IL-I[3 production and the maximal number
of these cytokine producing monocytes was noted
after 4 h of LPS stimulation (data not shown). Ap-
proximately 40% of the monocytes produced TNF0t
and IL-I within 4 h of LPS stimulation.
The percentage of IL-6-producing monocytes in
4-h cultures from different healthy donors varied
widely (range: 14-37%). The response to the two
drugs and percentage of IL-6 producing monocytes
among different donors also varied. However, both
FK506 and CsA increased the percentage of IL-6-
producing monocytes in a dose dependent manner
(Fig. 2). The increase of IL-6 producing monocytes
was observed at drug concentrations between
0.12 nM and 1.2 l.tM (0.1 and 1 000 ng/ml) for FK506
(Fig. 2A) and between 0.83 nM and 8.3 I.tM (1 and
10 000 ng/ml) for CsA (Fig. 2B). The concentration of
FK506 required to attain half the maximal stimulation
of IL-6 production was 6 nM (5 ng/ml), which was
calculated as the mean value of IL-6-producing cells
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FIG. 2. Dose dependent effects of FK506 or cyclosporin A on IL-6 produc-
tion by monocytes after LPS stimulation. Monocytes from five donors were
cultured with LPS (10 ng/ml) and the indicated concentrations of FK506 (A)
or cyclosporin A (B) for 4 h. Data are the mean S.D. of five experiments.
The effects are expressed as percentage of IL-6-producing monocytes
compared with those stimulated with LPS alone.
for five healthy donors. In the case of CsA, it was
42 nM (50 ng/mD. By comparison, to obtain the same
stimulating effect, the required dose of FK506 was 7-
fold lower than that of CsA.
In contrast, the percentage of LPS-stimulated
TNF(x- and IL-l-producing monocytes was slightly
decreased by FK506 and CsA, at doses up to 1.2 BM
(1 000ng/ml) and 8.3 l.tM (10 000 ng/mD, respec-
tively (Fig. 3). The percentage of TNF(x and IL-I-
producing monocytes was assessed every hour from
1 h to 6 h after LPS stimulation under the same
conditions; FK506 and CsA had little or no effect on
the production of each cytokine (data not shown).
Ethanol, which was used as the solvent, had no effect
on the production of these cytokines at a 100-fold
dilution. The viability of cells remained at more than
95% as assessed by trypan blue dye uptake under the
experimental conditions of this study.
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FIG. 3. Effects of FKS08 or cyclosporin A on TNFot and IL-1 [ production by
monocytes after LPS stimulation. Monocytes were cultured with LPS
(10 ng/ml) and the indicated concentrations of FK506 (A) or cyclosporin A
(B) for 4 h. The percentage of TNF(- and IL-1 -producing monocytes was
assessed. Representative data from one of three experiments are shown.
In the absence of LPS, the percentage of each cytokine-producing
monocytes was less than 2% (data not shown). (o) TNFoq (O) IL-lJ.
Next, the effect of FK506 and CsA on IL-6-produc-
tion was examined by stimulating monocytes with
various amount of LPS (Fig. 4). Monocytes were
cultured with LPS (100 pg/ml-lO lttg/mD and 12 nM
(lOng/ml) FK506, 0.83btM (1 O00ng/ml)CsA, or
medium. After 4 h of culture, the percentage of IL-6-
producing cells was assessed. The percentage of IL-
6-producing monocytes was about the same
(34.6%-36.6%) when stimulated with LPS alone at
doses ranging between 100 pg/ml and 10 ng/ml.
However, it increased when stimulated with LPS at
the concentrations of 10 ng/ml-lO btg/ml, in a dose
dependent manner. As shown in Fig. 4, both FK506
and CsA increased the percentage of IL-6-producing
monocytes when stimulated with 100 pg/ml-1 l.tg/ml
of LPS. At the concentration of 10 ng/ml of LPS, the
percentage of IL-6-producing monocytes cultured
with control medium, FK506 and CsA was 36.6%,
67.7% and 63.7%, respectively. That is, a 1.85-fold
increase for FK506 and a 1.74-fold increase for CsA
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FIG. 4. Effects of 1:!<506 or cyclosporin A on IL-6 production by monocytes
stimulated with various concentrations of LP$. Monocytes were cultured
with the indicated concentrations of LP$ and 12 nM (10 ng/ml) F1<506 (O),
0.83 pM (1 000 ng/ml) cyclosporin A (o), or medium (i-I). After 4 h culture,
the percentage of IL-6-producing monocytes was assessed. Representa-
tive data from one of four experiments are shown.
was noted. In contrast, when the monocytes were
stimulated with 10 btg/ml LPS, the percentage of IL-
6-producing monocytes is about the same (72.65% vs.
68.2% vs. 69.0%); that is, in the presence of a higher
concentration of LPS FK506 and CsA did not enhance
IL-6 production further.
Effect ofpretreatment orpost-treatment ofFK506and
cyclosporin A on I1-6 production in LPS stimulated
monocytes: Treatment of monocytes with FK506 or
CsA before LPS stimulation increased the percentage
of I1-6-producing monocytes after LPS stimulation
more than in control cultures (Table 1). Monocytes
were incubated with LPS for 5 min, 30 min or 4 h and
the percentage of IL-6-producing monocytes was
measured 4 h after the addition of LPS. Pretreatment
with FK506 increased the percentage of IL-6-produc-
ing monocytes to 20.55 _+ 0.07%, 22.05 _+ 1.20%, and
28.60 + 2.12%, after 5 min, 30 min and 4 h treatment
with LPS, respectively. Pretreatment with CsA also
increased the percentage of IL-6-producing
monocytes to 22.05 + 2.05%, 21.85 + 1.85%, and
25.49 _+ 0.49%, respectively. On the other hand, treat-
ment with FK506 and CsA after LPS stimulation had
no enhancing effect on the percentage of IL-6-pro-
ducing monocytes, as shown in Table 1.
Discussion
In this study it was found that FK506 and CsA
selectively enhanced the production of IL-6 in
monocytes stimulated with a low concentration of
LPS, whereas the percentage of LPS-stimulated
TNF0- and IL-l[-producing monocytes was slightly
suppressed by FK506 an CsA. In contrast, Andersson
et al. reported that FK506 and CsA had no effect on
LPS induced IL-6 production in monocytes. They
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Table 1. Effect of cyclosporin A and FK506 on the percentage of
IL-6-producing monocytes
Pretreatment" LPS Post-treatment Cytoplasmic IL-6
positive cells (%)
4 h 15.50 + 1.27
FK506 h 4 h 28.60 + 2.1
CsA h 4 h 25.49 + 0.49
5 min 12.40 + 0.87
FK506 h 5 min 20.55 + 0.07"
CsA h 5 min 22.05 + 2.05"
30 min 14.15 + 0.35
FK506 h 30 min 22.05 + 1.20
CsA h 30 min 21.85 + 1.85"
30 min 13.30 + 0.40
30 min FK506 h 13.90 + 0.14
30 min CsA h 15.05 + 0.78
30 min FK506 3.5 h 13.75 + 1.63
30 min CsA 3.5 h 14.85 + 0.07
0.50 + 0.50
FK506 h 0.50 + 0.50
CsA h 0.50 + 0.50
"Monocytes were incubated with or without 12 nM (10 ng/ml)
FK506 or 0.83 l.tM (1 000 ng/ml) cyclosporin A for h before LPS
stimulation.
bMonocytes were stimulated or not stimulated with 10 ng/ml LPS for
the indicated periods of time.
CMonocytes were incubated with or without 12 nM (10 ng/ml)
FK506 or 0.83 l.tM (1 000 ng/ml) cyclosporin A for h or 3.5 h after
LPS stimulation.
Percentages of IL-6-producing cells were determined 4 h after the
initiation of LPS stimulation. Data are shown as the mean + S.D. in
triplicate culture.
"p < 0.05; lp < 0.01 (vs. controls with LPS for 30 min). p values are
given when statistically significant.
added LPS at a concentration of 100 ng/ml. Our
observations suggest that the LPS concentrations
employed might account for these differences. Al-
though in our study neither drug had an enhancing
effect on the number of IL-6-producing monocytes
when stimulated with a high concentration of LPS,
both FK506 and CsA did increase the percentage of
IL-6-producing monocytes when the cells were
stimulated with low concentrations of LPS (10 ng/
ml). Secondly, the different procedures might also
account for the different results obtained by
Andersson et al. because multiple-square glass
slides were used to separate and culture adherent
monocytes as well as for immunocytochemistry. 13,14
On the other hand, it has been suggested that adher-
ence of monocytes would lead to IL-6 production,15a6
but the present observations did not support these
speculations since no or very low IL-6 production
(< 2% monocytes) occurred when cells were cultured
without LPS.
Stimulating effects by FK506, as observed in
this study, are not surprising because it is known
that FK506 had a stimulating effect on the growth
of colony-forming units/granulocyte-macrophage
(CFU-GM) and burst-forming units/erythroid
(BFU-E) from peripheral blood and cord blood
cells, although the precise mechanism remains
unclear.
In the present study, pretreatment with FK506 and
CsA followed by LPS increased the percentage of IL-
6-producing monocytes but post-treatment with ei-
ther drug had no effect, suggesting that the enhanc-
ing effect of each drug is exerted before LPS stimu-
lation or at an early stage of the post-receptor path-
way after LPS stimulation. Therefore, the different
effects of FK506 and CsA on monocytes stimulated
with low and high concentrations of LPS may be
exerted via different receptors. One possible receptor
for LPS is CD14, which is the receptor for LPS-LPS
binding protein (LBP) on monocytes. 17 In this model,
LBP promotes the sensitivity of monocytes to LPS by
both lowering the threshold and accelerating the
time course of cytokine production. LPS interacts
with LBP and the LPS-LBP complex binds to CD14,
leading to monocyte activation for cytokine produc-
tion. 17’18 Monocytes are also stimulated by high con-
centrations of LPS in the absence of LBP probably via
putative LPS receptors that are independent of LBP
and CD14.19 Similarly, in our study, low concentra-
tions of LPS may stimulate monocytes via CD14 but
high concentrations of LPS may stimulate monocytes
via other LPS receptors on their surface. The different
receptors and subsequent intracellular signalling
pathways may determine the type of effect of FK506
and CsA. Although various LPS binding sites have
been identified on monocytes, no physiological defi-
nite LPS receptor has yet been demonstrated,a So the
precise details of this possibility remain to be deter-
mined.
The enhancing effect of FK506 and CsA on
monocytes may be due to the inhibition of
calcineurin, similar to the T-cell suppressive effect, by
the two drugs. FK506 inhibits T-cell function at
concentrations 7 to 70 times lower than CsA. 21’22
While FK506 shares no structural similarity with CsA,
both drugs appear to inhibit T-cell signalling
pathways by similar mechanisms which involve
the Cai+-calmodulin dependent serine/threonine
phosphatase calcineurin pathway.3,24 CsA and FK506
inhibit calcineurin after binding to their respective
receptor proteins, Cyclophilin and FK506-binding
protein (FKBP). This inhibition is specific for
calcineurin. The CsA-cyclophilin complex and the
FK506-FKBP complex were found to bind to and
inhibit calcineurin. Accordingly, the observation that
the two drugs increased the percentage of IL-6-
producing monocyte suggests that inhibition of
calcineurin might be related to this enhancement. In
the present study the concentration of either FK506
or CsA required for this enhancement is similar to the
concentrations at which both drugs can cause T-cell
immunosuppression. Moreover, the optimal effect of
FK506 was achieved at a concentration 7-fold lower
than that of CsA. The concentration of FK506 re-
quired to inhibit calcineurin dependent cell function
should depend on relative amounts of FKBP and
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calcineurin in the cells. 25 The concentrations of FKBP
and calcineurin in monocytes or lymphocytes are not
known, and this makes comparison difficult. Further
functional analyses are required to determine the
function of calcineurin on monocytes and T cells.
Cytokine production at a single-cell level was stud-
ied by an immunocytochemical method performed
essentially, as described previously by Sander et al.
IL-6 and TNF0t showed a local, perinuclear staining
reflecting the accumulation adjacent to the nucleus,
while IL-11 staining has resulted in more diffuse
cytoplasmic staining. Similar experiences have been
reported by other groups. 12,26 Sander et al.12 men-
tioned that the characteristic staining pattern of IL-6
and TNFt is seen in cytokine-producing cells rather
than during cytokine uptake and it reflects the accu-
mulation of cytokines in the Golgi organelle. The
diffuse cytoplasmic staining, on the other hand,
would indicate that the intracellular transport of IL-
1 follows a different pathway from the classical
endoplasmic reticulum-Golgi route.27 It was con-
firmed that the ABC method can be used to detect
cytoplasmic cytokines. This method is more useful
than immunofluorescence techniques because it
does not need an immunofluorescence microscope
and allowed long-term morphological evaluation.
Dysregulation of IL-6 production is often associ-
ated with pathological conditions that involve abnor-
mal B-cell proliferation in multiple myeloma and
lymphoproliferative disorders.1 IL-6 is an essential
growth factor for myeloma cells and the elevated
serum levels appear to correlate with the severity of
the disease.1 Moreover, IL-6 induces massive
plasmacytosis with autoantibody production in IL-6
transgenic mice. 28 On the other hand, CsA-treated
patients showed evidence of an increased incidence
of polyclonal lymphoproliferative disorders and B
cell lymphomas, and their risk of developing
lymphoma is related to the degree and duration of
their immunosuppression. 29 In addition, CsA could
facilitate the development of Epstein-Barr virus
(EBV)-transformed B cell lymphomas via
potentiation of the IL-6 production.3 Therefore, the
potentiation of the production of IL-6 by FK506 or
CsA may have an undesirable outcome on patients
with multiple myeloma or lymphoproliferative disor-
ders, where prolonged administration of these drugs
might be anticipated.
In conclusion, FK506 and CsA can selectively
enhance IL-6 production in monocytes stimulated
with low concentrations of LPS, although neither
drug can enhance it when monocytes are stimulated
with high concentrations of LPS. It should be noted
from our observation that the enhancement of
cytokine production by FK506 and CsA can occur in
the presence of very low amount of LPS and influ-
ence the cytokine network in vitro and, possibly,
also in vivo.
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